Status: current, Primitive. Date: 31-Jul 2019. Module: SNOMED CT core
Descriptions:
Id | Description | Lang | Type | Status | Case? | Module |
3773045010 | Vascular endothelial growth factor receptor antagonist (disposition) | en | Fully specified name | Active | Case insensitive | SNOMED CT core |
3773046011 | Vascular endothelial growth factor receptor antagonist | en | Synonym | Active | Case insensitive | SNOMED CT core |
4167521016 | VEGF antagonist | en | Synonym | Active | Case sensitive | SNOMED CT core |
Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
Vascular endothelial growth factor receptor antagonist | Is a | Receptor antagonist | true | Inferred relationship | Some |
Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
Sunitinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Vascular endothelial growth factor receptor antagonist | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Sunitinib malate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Bevacizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Ranibizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Pegaptanib sodium | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Sorafenib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Pegaptanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Vandetanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Axitinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Sorafenib tosylate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Cabozantinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Lenvatinib mesilate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Pazopanib hydrochloride | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Pazopanib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Lenvatinib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Ramucirumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Regorafenib | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Aflibercept | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Brolucizumab | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some | |
Cabozantinib s-malate | Has disposition | True | Vascular endothelial growth factor receptor antagonist | Inferred relationship | Some |
Reference Sets
Qualifier value foundation reference set
Australian dialect reference set